CERS
Cerus Corporation
There isn't enough reported data to score CERS yet.
LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
CERS Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Under pressure | |
| Unavailable | |
| Weak |
CERS's profitability and balance sheet are currently under pressure. There isn't enough data to rate its revenue and cash flow.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
CERS PE Valuation
CERS has no meaningful PE right now: it lost money over the past year.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
CERS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Growth | |
| Strongly improving | |
| Limited | |
| High |
Analysts expect CERS's losses to shrink, with revenue growing.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
CERS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.03 | +$0.05 |
| Q2 2026 | -$0.03 | +$0.07 |
| Q1 2026 | -$0.05 | +$0.05 |
| Q4 2025 | -$0.08 | +$0.03 |
| Q3 2025 | -$0.08 | +$0.03 |
| Q2 2025 | -$0.10 | +$0.03 |
| Q1 2025 | -$0.10 | +$0.07 |
| Q4 2024 | -$0.11 | +$0.10 |
CERS is still losing money, but far less than before: $0.03 per share over the past year, against $0.52 at its worst in late 2019.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.83 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over CERS on earnings quality, reporting a profit while its opponent remains loss making.
CERS Quarterly Revenue
CERS and LLY do not have enough comparable growth data to identify a winner.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 0.7% | N/A |
| Q2 2026 | -3.2% | N/A |
| Q1 2026 | -0.7% | N/A |
LLY has the edge over CERS on profitability, with a higher operating margin.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY's revenue has grown year over year for 14 quarters in a row: $24.4B last quarter, up 39% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over CERS on profitability, with a higher operating margin.
CERS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $2.4M | +2471% |
| Q2 2026 | -$3.5M | -$611K |
| Q1 2026 | -$3.3M | -$2.3M |
| Q4 2025 | $4.9M | +24% |
| Q3 2025 | $94K | -97% |
| Q2 2025 | -$2.9M | -912% |
| Q1 2025 | -$956K | -211% |
| Q4 2024 | $4M | +$19.1M |
CERS has burned cash in most quarters: $494,000 over the past year, up 194% from the year before.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over CERS on cash flow, with more consistent year-over-year improvement.
CERS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.5% | +1.1M shares |
| 1 year | +5.1% | +9.8M shares |
| 3 years | +11% | +20.7M shares |
| 5 years | +17% | +29.7M shares |
| Available history | +44% | +61.8M shares |
CERS has 202M diluted shares, up 5.1% from a year ago.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over CERS on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
CERS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 711.2x | High |
CERS's net debt is more than 20 years of its operating earnings (EBITDA).
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY has the edge over CERS on leverage, with a lower net debt burden relative to earnings.
CERS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 40.0 | Neutral |
| Stochastic | 8.0 | Oversold |
CERS's weekly RSI is 40 (neutral) and its Stochastic is 8 (oversold).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
CERS PE vs Healthcare Sector
CERS has no meaningful PE right now: it lost money over the past year.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
CERS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.24 | 13% below |
| 20 week MA | $2.55 | 24% below |
| 50 week MA | $2.39 | 19% below |
| 100 week MA | $1.93 | 0.5% above |
| 200 week MA | $2.00 | 3% below |
CERS's trend is mixed: it's above one of its five weekly moving averages, and 3% below its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over CERS on trend strength, trading above more of its moving averages.
CERS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $4.28 | $8.07 | +89% |
| 2021 | $8.07 | $6.95 | -14% |
| 2022 | $6.95 | $3.71 | -47% |
| 2023 | $3.71 | $2.16 | -42% |
| 2024 | $2.16 | $1.56 | -28% |
| 2025 | $1.56 | $2.03 | +30% |
| 2026 YTD | $2.03 | $1.94 | -4.4% |
CERS has finished lower in four of the last six years. It's down 4.4% so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over CERS on returns for 2026, with the stronger performance.